Skip to main content
SpringerLink
Log in

Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

Dosimetry is critical to achieve the optimal therapeutic effect of radioligand therapy (RLT) with limited side effects. Our aim was to perform image-based absorbed dose calculation for the new PSMA ligand 177Lu-DKFZ-PSMA-617 in support of its use for the treatment of metastatic prostate cancer.

Methods

Whole-body planar images and SPECT/CT images of the abdomen were acquired in five patients (mean age 68 years) for during two treatment cycles at approximately 1, 24, 48 and 72 h after administration of 3.6 GBq (range 3.4 to 3.9 GBq) 177Lu-DKFZ-PSMA-617. Quantitative 3D SPECT OSEM reconstruction was performed with corrections for photon scatter, photon attenuation and detector blurring. A camera-specific calibration factor derived from phantom measurements was used for quantitation. Absorbed doses were calculated for various organs from the images using a combination of linear approximation, exponential fit, and target-specific S values, in accordance with the MIRD scheme. Absorbed doses to bone marrow were estimated from planar and SPECT images and with consideration of the blood sampling method according to the EANM guidelines.

Results

The average (± SD) absorbed doses per cycle were 2.2 ± 0.6 Gy for the kidneys (0.6 Gy/GBq), 5.1 ± 1.8 Gy for the salivary glands (1.4 Gy/GBq), 0.4 ± 0.2 Gy for the liver (0.1 Gy/GBq), 0.4 ± 0.1 Gy for the spleen (0.1 Gy/GBq), and 44 ± 19 mGy for the bone marrow (0.012 Gy/GBq). The organ absorbed doses did not differ significantly between cycles. The critical absorbed dose reported for the kidneys (23 Gy) was not reached in any patient. At 24 h there was increased uptake in the colon with 50 – 70 % overlap to the kidneys on planar images. Absorbed doses for tumour lesions ranged between 1.2 and 47.5 Gy (13.1 Gy/GBq) per cycle.

Conclusion

The salivary glands and kidneys showed high, but not critical, absorbed doses after RLT with 177Lu-DKFZ-PSMA-617. We suggest that 177Lu-DKFZ-PSMA-617 is suitable for radiotherapy, offering tumour-to-kidney ratios comparable to those with RLT agents currently available for the treatment of neuroendocrine tumours. Our dosimetry results suggest that 177Lu-DKFZ-PSMA-617 treatment with higher activities and more cycles is possible without the risk of damaging the kidneys.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–128.

    Article  PubMed  Google Scholar 

  2. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.

    Article  CAS  PubMed  Google Scholar 

  3. Pond GR, Sonpavde G, de Wit R, Eisenberger MA, Tannock IF, Armstrong AJ. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur Urol. 2014;65:3–6.

    Article  PubMed  Google Scholar 

  4. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528–39.

    Article  CAS  PubMed  Google Scholar 

  5. Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, et al. Radiation dosimetry and first therapy results with a (124)I/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41:1280–92.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, et al. Phase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19:5182–91.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol. 2004;22:2522–31.

    Article  CAS  PubMed  Google Scholar 

  8. Benesova M, Schafer M, Bauder-Wust U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914–20.

    Article  CAS  PubMed  Google Scholar 

  9. Delker A, Ilhan H, Zach C, Brosch J, Gildehaus F-J, Lehner S, et al. The influence of early measurements onto the estimated kidney dose in 177Lu-DOTATATE peptide receptor radiotherapy of neuroendocrine tumors. Mol Imaging Biol. 2015. doi:10.1007/s11307-015-0839-3.

    PubMed  Google Scholar 

  10. Kohli V, King MA, Glick SJ, Pan TS. Comparison of frequency-distance relationship and gaussian-diffusion-based methods of compensation for distance-dependent spatial resolution in SPECT imaging. Phys Med Biol. 1998;43:1025–37.

    Article  CAS  PubMed  Google Scholar 

  11. Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging. 1994;13:601–9.

    Article  CAS  PubMed  Google Scholar 

  12. Wallis JW, Miller TR. An optimal rotator for iterative reconstruction. IEEE Trans Med Imaging. 1997;16:118–23.

    Article  CAS  PubMed  Google Scholar 

  13. Green PJ. Bayesian reconstructions from emission tomography data using a modified EM algorithm. IEEE Trans Med Imaging. 1990;9:84–93.

    Article  CAS  PubMed  Google Scholar 

  14. Beekman FJ, Kamphuis C, Frey EC. Scatter compensation methods in 3D iterative SPECT reconstruction: a simulation study. Phys Med Biol. 1997;42:1619–32.

    Article  CAS  PubMed  Google Scholar 

  15. Bai CY, Shao L, Da Silva AJ, Zhao Z. A generalized model for the conversion from CT numbers to linear attenuation coefficients. IEEE Trans Nucl Sci. 2003;50:1510–5.

    Article  Google Scholar 

  16. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–30.

    Article  CAS  PubMed  Google Scholar 

  17. Stabin MS, Hunt, J, Brill, A, Sparks R, Eckerman K, Bertelli L. RADAR: the radiation dose assessment resource. www.doseinfo-radar.com. 2001.

  18. Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys. 2003;85:294–310.

    Article  CAS  PubMed  Google Scholar 

  19. Williams LE, Liu A, Yamauchi DM, Lopatin G, Raubitschek AA, Wong JY. The two types of correction of absorbed dose estimates for internal emitters. Cancer. 2002;94:1231–4.

    Article  PubMed  Google Scholar 

  20. Hindorf C, Glatting G, Chiesa C, Linden O, Flux G; EANM Dosimetry Committee. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging. 2010;37:1238–50.

    Article  PubMed  Google Scholar 

  21. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689–94.

    CAS  PubMed  Google Scholar 

  22. Traino AC, Ferrari M, Cremonesi M, Stabin MG. Influence of total-body mass on the scaling of S-factors for patient-specific, blood-based red-marrow dosimetry. Phys Med Biol. 2007;52:5231–48.

    Article  CAS  PubMed  Google Scholar 

  23. Dewaraja YK, Frey EC, Sgouros G, Brill AB, Roberson P, Zanzonico PB, et al. MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy. J Nucl Med. 2012;53:1310–25.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Sanders J, Kuwert T, Hornegger J, Ritt P. Quantitative SPECT/CT imaging of 177Lu with in vivo validation in patients undergoing peptide receptor radionuclide therapy. Mol Imaging Biol. 2015;17:585–93.

    Article  CAS  PubMed  Google Scholar 

  25. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart H, Hadaschik B, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95.

    Article  CAS  PubMed  Google Scholar 

  26. Gordon IO, Tretiakova MS, Noffsinger AE, Hart J, Reuter VE, Al-Ahmadie HA. Prostate-specific membrane antigen expression in regeneration and repair. Mod Pathol. 2008;21:1421–7.

    Article  CAS  PubMed  Google Scholar 

  27. Maraj B, Aldersley M, Markham A. Prostate-specific membrane antigen expression in the duodenum: implications in coeliac disease and immunotherapy for prostate cancer. Lancet. 1998;351:1559–60.

    Article  CAS  PubMed  Google Scholar 

  28. Silver DA, Pellicer I, Fair WR, Heston W, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–5.

    CAS  PubMed  Google Scholar 

  29. Gensheimer MF, Liao JJ, Garden AS, Laramore GE, Parvathaneni U. Submandibular gland-sparing radiation therapy for locally advanced oropharyngeal squamous cell carcinoma: patterns of failure and xerostomia outcomes. Radiat Oncol. 2014;9:255.

    Article  PubMed Central  PubMed  Google Scholar 

  30. Hey J, Setz J, Gerlach R, Janich M, Hildebrandt G, Vordermark D, et al. Parotid gland-recovery after radiotherapy in the head and neck region – 36 months follow-up of a prospective clinical study. Radiat Oncol. 2011;6:125.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23:4591–601.

    Article  CAS  PubMed  Google Scholar 

  32. Vallabhajosula S, Kuji I, Hamacher KA, Konishi S, Kostakoglu L, Kothari PA, et al. Pharmacokinetics and biodistribution of 111In-and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? J Nucl Med. 2005;46:634–41.

    CAS  PubMed  Google Scholar 

  33. Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0, Tyr3] octreotate. Eur J Nucl Med Mol Imaging. 2009;36:1138–46.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Larson SM, Raubitschek A, Reynolds JC, Neumann RD, Hellstrom K-E, Hellstrom I, et al. Comparison of bone marrow dosimetry and toxic effect of high dose 131I-labeled monoclonal antibodies administered to man. Int J Radiat Appl Instrumen B. 1989;16:153–8.

    Article  CAS  Google Scholar 

  35. Siegel J, Wessels B, Watson E, Stabin M, Vriesendorp H, Bradley E, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconjug Radiopharm. 1990;3:213–34.

    Google Scholar 

  36. Bodei L, Cremonesi M, Grana CM, Chinol M, Baio SM, Severi S, et al. Yttrium-labelled peptides for therapy of NET. Eur J Nucl Med Mol Imaging. 2012;39:93–102.

    Article  CAS  Google Scholar 

  37. Kam B, Teunissen J, Krenning E, De Herder W, Khan S, van Vliet E, et al. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39:103–12.

    Article  PubMed Central  CAS  Google Scholar 

  38. Sandström M, Garske-Román U, Granberg D, Johansson S, Widström C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013;54:33–41.

    Article  PubMed  Google Scholar 

  39. Wild D, Fani M, Fischer R, Del Pozzo L, Kaul F, Krebs S, et al. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nucl Med. 2014;55:1248–52.

    Article  CAS  PubMed  Google Scholar 

  40. Emami B, Lyman J, Brown A, Cola L, Goitein M, Munzenrider J, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–22.

    Article  CAS  PubMed  Google Scholar 

  41. Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Horsch D, O’Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800–16.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  42. Garske U, Sandström M, Johansson S, Sundin A, Granberg D, Eriksson B, et al. Minor changes in effective half-life during fractionated 177Lu-octreotate therapy. Acta Oncol. 2012;51:86–96.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank their colleagues from the Department of Nuclear Medicine for their participation in data collection, with particular thanks to the skilled nuclear medicine technicians who performed the imaging studies. U. Haberkorn was supported by a grant from the Klaus-Tschira foundation (grant number 00.198.2012). The manuscript was edited by Inglewood Biomedical Editing.

Compliance with ethical standards

ᅟ

Funding

This study was partially funded by the German Cancer Consortium (DKTK).

Conflicts of interest

None.

Informed consent

For this type of study formal consent is not required.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Marchioninistrasse 15, 81377, Munich, Germany

    Andreas Delker, Wolfgang Peter Fendler, Anika Brunegraf, Astrid Gosewisch, Franz Josef Gildehaus, Peter Bartenstein & Guido Böning

  2. Department for Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany

    Clemens Kratochwil & Uwe Haberkorn

  3. Department of Urology, Ludwig-Maximilians-University of Munich, Munich, Germany

    Stefan Tritschler & Christian Georg Stief

  4. Division of Radiopharmaceutical Chemistry, German Cancer Research Center (dkfz), Heidelberg, Germany

    Klaus Kopka

Authors
  1. Andreas Delker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wolfgang Peter Fendler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Clemens Kratochwil
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anika Brunegraf
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Astrid Gosewisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Franz Josef Gildehaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Stefan Tritschler
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Christian Georg Stief
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Klaus Kopka
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Uwe Haberkorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Peter Bartenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Guido Böning
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guido Böning.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Delker, A., Fendler, W.P., Kratochwil, C. et al. Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging 43, 42–51 (2016). https://doi.org/10.1007/s00259-015-3174-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-015-3174-7

Keywords

Search

Navigation